In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression

Che Ming Liu, Chia Ling Hsieh, Yun Chi He, Sen Jei Lo, Ji An Liang, Teng Fu Hsieh, Sajni Josson, Leland W K Chung, Mien Chie Hung, Shian Ying Sung

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cancer cells respond to stress by activating a variety of survival signaling pathways. A disintegrin and metalloproteinase (ADAM) 9 is upregulated during cancer progression and hormone therapy, functioning in part through an increase in reactive oxygen species. Here, we present in vitro and in vivo evidence that therapeutic targeting of ADAM9 gene expression by lentivirus-delivered small hairpin RNA (shRNA) significantly inhibited proliferation of human prostate cancer cell lines and blocked tumor growth in a murine model of prostate cancer bone metastasis. Cell cycle studies confirmed an increase in the G1-phase and decrease in the S-phase population of cancer cells under starvation stress conditions, which correlated with elevated intracellular superoxide levels. Microarray data showed significantly decreased levels of regenerating islet-derived family member 4 (REG4) expression in prostate cancer cells with knockdown of ADAM9 gene expression. This REG4 downregulation also resulted in induction of expression of p21Cip1/WAF1, which negatively regulates cyclin D1 and blocks the G1/S transition. Our data reveal a novel molecular mechanism of ADAM9 in the regulation of prostate cancer cell proliferation, and suggests a combined modality of ADAM9 shRNA gene therapy and cytotoxic agents for hormone refractory and bone metastatic prostate cancer.

Original languageEnglish
Article numbere53795
JournalPLoS One
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 16 2013
Externally publishedYes

Fingerprint

Lentivirus
prostatic neoplasms
Gene expression
Small Interfering RNA
cell cycle
Prostatic Neoplasms
Cell Cycle
Cells
RNA
Gene Expression
gene expression
Growth
interphase
Bone
hormones
bones
Hormones
Disintegrins
Gene therapy
Bone Neoplasms

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression. / Liu, Che Ming; Hsieh, Chia Ling; He, Yun Chi; Lo, Sen Jei; Liang, Ji An; Hsieh, Teng Fu; Josson, Sajni; Chung, Leland W K; Hung, Mien Chie; Sung, Shian Ying.

In: PLoS One, Vol. 8, No. 1, e53795, 16.01.2013.

Research output: Contribution to journalArticle

Liu, Che Ming ; Hsieh, Chia Ling ; He, Yun Chi ; Lo, Sen Jei ; Liang, Ji An ; Hsieh, Teng Fu ; Josson, Sajni ; Chung, Leland W K ; Hung, Mien Chie ; Sung, Shian Ying. / In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression. In: PLoS One. 2013 ; Vol. 8, No. 1.
@article{a3f388d34f424ab7b39e051d5b6c879a,
title = "In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression",
abstract = "Cancer cells respond to stress by activating a variety of survival signaling pathways. A disintegrin and metalloproteinase (ADAM) 9 is upregulated during cancer progression and hormone therapy, functioning in part through an increase in reactive oxygen species. Here, we present in vitro and in vivo evidence that therapeutic targeting of ADAM9 gene expression by lentivirus-delivered small hairpin RNA (shRNA) significantly inhibited proliferation of human prostate cancer cell lines and blocked tumor growth in a murine model of prostate cancer bone metastasis. Cell cycle studies confirmed an increase in the G1-phase and decrease in the S-phase population of cancer cells under starvation stress conditions, which correlated with elevated intracellular superoxide levels. Microarray data showed significantly decreased levels of regenerating islet-derived family member 4 (REG4) expression in prostate cancer cells with knockdown of ADAM9 gene expression. This REG4 downregulation also resulted in induction of expression of p21Cip1/WAF1, which negatively regulates cyclin D1 and blocks the G1/S transition. Our data reveal a novel molecular mechanism of ADAM9 in the regulation of prostate cancer cell proliferation, and suggests a combined modality of ADAM9 shRNA gene therapy and cytotoxic agents for hormone refractory and bone metastatic prostate cancer.",
author = "Liu, {Che Ming} and Hsieh, {Chia Ling} and He, {Yun Chi} and Lo, {Sen Jei} and Liang, {Ji An} and Hsieh, {Teng Fu} and Sajni Josson and Chung, {Leland W K} and Hung, {Mien Chie} and Sung, {Shian Ying}",
year = "2013",
month = "1",
day = "16",
doi = "10.1371/journal.pone.0053795",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression

AU - Liu, Che Ming

AU - Hsieh, Chia Ling

AU - He, Yun Chi

AU - Lo, Sen Jei

AU - Liang, Ji An

AU - Hsieh, Teng Fu

AU - Josson, Sajni

AU - Chung, Leland W K

AU - Hung, Mien Chie

AU - Sung, Shian Ying

PY - 2013/1/16

Y1 - 2013/1/16

N2 - Cancer cells respond to stress by activating a variety of survival signaling pathways. A disintegrin and metalloproteinase (ADAM) 9 is upregulated during cancer progression and hormone therapy, functioning in part through an increase in reactive oxygen species. Here, we present in vitro and in vivo evidence that therapeutic targeting of ADAM9 gene expression by lentivirus-delivered small hairpin RNA (shRNA) significantly inhibited proliferation of human prostate cancer cell lines and blocked tumor growth in a murine model of prostate cancer bone metastasis. Cell cycle studies confirmed an increase in the G1-phase and decrease in the S-phase population of cancer cells under starvation stress conditions, which correlated with elevated intracellular superoxide levels. Microarray data showed significantly decreased levels of regenerating islet-derived family member 4 (REG4) expression in prostate cancer cells with knockdown of ADAM9 gene expression. This REG4 downregulation also resulted in induction of expression of p21Cip1/WAF1, which negatively regulates cyclin D1 and blocks the G1/S transition. Our data reveal a novel molecular mechanism of ADAM9 in the regulation of prostate cancer cell proliferation, and suggests a combined modality of ADAM9 shRNA gene therapy and cytotoxic agents for hormone refractory and bone metastatic prostate cancer.

AB - Cancer cells respond to stress by activating a variety of survival signaling pathways. A disintegrin and metalloproteinase (ADAM) 9 is upregulated during cancer progression and hormone therapy, functioning in part through an increase in reactive oxygen species. Here, we present in vitro and in vivo evidence that therapeutic targeting of ADAM9 gene expression by lentivirus-delivered small hairpin RNA (shRNA) significantly inhibited proliferation of human prostate cancer cell lines and blocked tumor growth in a murine model of prostate cancer bone metastasis. Cell cycle studies confirmed an increase in the G1-phase and decrease in the S-phase population of cancer cells under starvation stress conditions, which correlated with elevated intracellular superoxide levels. Microarray data showed significantly decreased levels of regenerating islet-derived family member 4 (REG4) expression in prostate cancer cells with knockdown of ADAM9 gene expression. This REG4 downregulation also resulted in induction of expression of p21Cip1/WAF1, which negatively regulates cyclin D1 and blocks the G1/S transition. Our data reveal a novel molecular mechanism of ADAM9 in the regulation of prostate cancer cell proliferation, and suggests a combined modality of ADAM9 shRNA gene therapy and cytotoxic agents for hormone refractory and bone metastatic prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84872448443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872448443&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0053795

DO - 10.1371/journal.pone.0053795

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e53795

ER -